These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

486 related articles for article (PubMed ID: 30355322)

  • 1. FUNDAMANT: an interventional 72-week phase 1 follow-up study of AADvac1, an active immunotherapy against tau protein pathology in Alzheimer's disease.
    Novak P; Schmidt R; Kontsekova E; Kovacech B; Smolek T; Katina S; Fialova L; Prcina M; Parrak V; Dal-Bianco P; Brunner M; Staffen W; Rainer M; Ondrus M; Ropele S; Smisek M; Sivak R; Zilka N; Winblad B; Novak M
    Alzheimers Res Ther; 2018 Oct; 10(1):108. PubMed ID: 30355322
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 1 trial.
    Novak P; Schmidt R; Kontsekova E; Zilka N; Kovacech B; Skrabana R; Vince-Kazmerova Z; Katina S; Fialova L; Prcina M; Parrak V; Dal-Bianco P; Brunner M; Staffen W; Rainer M; Ondrus M; Ropele S; Smisek M; Sivak R; Winblad B; Novak M
    Lancet Neurol; 2017 Feb; 16(2):123-134. PubMed ID: 27955995
    [TBL] [Abstract][Full Text] [Related]  

  • 3. AADvac1, an Active Immunotherapy for Alzheimer's Disease and Non Alzheimer Tauopathies: An Overview of Preclinical and Clinical Development.
    Novak P; Zilka N; Zilkova M; Kovacech B; Skrabana R; Ondrus M; Fialova L; Kontsekova E; Otto M; Novak M
    J Prev Alzheimers Dis; 2019; 6(1):63-69. PubMed ID: 30569088
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ADAMANT: a placebo-controlled randomized phase 2 study of AADvac1, an active immunotherapy against pathological tau in Alzheimer's disease.
    Novak P; Kovacech B; Katina S; Schmidt R; Scheltens P; Kontsekova E; Ropele S; Fialova L; Kramberger M; Paulenka-Ivanovova N; Smisek M; Hanes J; Stevens E; Kovac A; Sutovsky S; Parrak V; Koson P; Prcina M; Galba J; Cente M; Hromadka T; Filipcik P; Piestansky J; Samcova M; Prenn-Gologranc C; Sivak R; Froelich L; Fresser M; Rakusa M; Harrison J; Hort J; Otto M; Tosun D; Ondrus M; Winblad B; Novak M; Zilka N
    Nat Aging; 2021 Jun; 1(6):521-534. PubMed ID: 37117834
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety, tolerability and immunogenicity of an active anti-Aβ
    Lacosta AM; Pascual-Lucas M; Pesini P; Casabona D; Pérez-Grijalba V; Marcos-Campos I; Sarasa L; Canudas J; Badi H; Monleón I; San-José I; Munuera J; Rodríguez-Gómez O; Abdelnour C; Lafuente A; Buendía M; Boada M; Tárraga L; Ruiz A; Sarasa M
    Alzheimers Res Ther; 2018 Jan; 10(1):12. PubMed ID: 29378651
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First-in-man tau vaccine targeting structural determinants essential for pathological tau-tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer's disease model.
    Kontsekova E; Zilka N; Kovacech B; Novak P; Novak M
    Alzheimers Res Ther; 2014; 6(4):44. PubMed ID: 25478017
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study.
    Winblad B; Andreasen N; Minthon L; Floesser A; Imbert G; Dumortier T; Maguire RP; Blennow K; Lundmark J; Staufenbiel M; Orgogozo JM; Graf A
    Lancet Neurol; 2012 Jul; 11(7):597-604. PubMed ID: 22677258
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy assessment of an active tau immunotherapy in Alzheimer's disease patients with amyloid and tau pathology: a post hoc analysis of the "ADAMANT" randomised, placebo-controlled, double-blind, multi-centre, phase 2 clinical trial.
    Cullen NC; Novak P; Tosun D; Kovacech B; Hanes J; Kontsekova E; Fresser M; Ropele S; Feldman HH; Schmidt R; Winblad B; Zilka N
    EBioMedicine; 2024 Jan; 99():104923. PubMed ID: 38101301
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapy for Alzheimer's disease: from anti-β-amyloid to tau-based immunization strategies.
    Panza F; Frisardi V; Solfrizzi V; Imbimbo BP; Logroscino G; Santamato A; Greco A; Seripa D; Pilotto A
    Immunotherapy; 2012 Feb; 4(2):213-38. PubMed ID: 22339463
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Abeta DNA vaccination for Alzheimer's disease: focus on disease prevention.
    Cribbs DH
    CNS Neurol Disord Drug Targets; 2010 Apr; 9(2):207-16. PubMed ID: 20205639
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical trials of amyloid-based immunotherapy for Alzheimer's disease: end of beginning or beginning of end?
    Li Y; Liu Y; Wang Z; Jiang Y
    Expert Opin Biol Ther; 2013 Nov; 13(11):1515-22. PubMed ID: 24053611
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial.
    Gauthier S; Feldman HH; Schneider LS; Wilcock GK; Frisoni GB; Hardlund JH; Moebius HJ; Bentham P; Kook KA; Wischik DJ; Schelter BO; Davis CS; Staff RT; Bracoud L; Shamsi K; Storey JM; Harrington CR; Wischik CM
    Lancet; 2016 Dec; 388(10062):2873-2884. PubMed ID: 27863809
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Development of antibodies for immunotherapy of Alzheimer's disease].
    Matsumoto SE; Jin H; Takeda K; Hasegawa Y; Motoi Y; Hattori N; Tabira T
    Rinsho Shinkeigaku; 2012; 52(11):1168-70. PubMed ID: 23196552
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ABT-126 monotherapy in mild-to-moderate Alzheimer's dementia: randomized double-blind, placebo and active controlled adaptive trial and open-label extension.
    Gault LM; Lenz RA; Ritchie CW; Meier A; Othman AA; Tang Q; Berry S; Pritchett Y; Robieson WZ
    Alzheimers Res Ther; 2016 Oct; 8(1):44. PubMed ID: 27756421
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tau-based therapeutics for Alzheimer's disease: active and passive immunotherapy.
    Panza F; Solfrizzi V; Seripa D; Imbimbo BP; Lozupone M; Santamato A; Tortelli R; Galizia I; Prete C; Daniele A; Pilotto A; Greco A; Logroscino G
    Immunotherapy; 2016 Sep; 8(9):1119-34. PubMed ID: 27485083
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tau passive immunization inhibits not only tau but also Aβ pathology.
    Dai CL; Tung YC; Liu F; Gong CX; Iqbal K
    Alzheimers Res Ther; 2017 Jan; 9(1):1. PubMed ID: 28073379
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bapineuzumab for mild to moderate Alzheimer's disease in two global, randomized, phase 3 trials.
    Vandenberghe R; Rinne JO; Boada M; Katayama S; Scheltens P; Vellas B; Tuchman M; Gass A; Fiebach JB; Hill D; Lobello K; Li D; McRae T; Lucas P; Evans I; Booth K; Luscan G; Wyman BT; Hua L; Yang L; Brashear HR; Black RS;
    Alzheimers Res Ther; 2016 May; 8(1):18. PubMed ID: 27176461
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tau aggregation inhibitor therapy: an exploratory phase 2 study in mild or moderate Alzheimer's disease.
    Wischik CM; Staff RT; Wischik DJ; Bentham P; Murray AD; Storey JM; Kook KA; Harrington CR
    J Alzheimers Dis; 2015; 44(2):705-20. PubMed ID: 25550228
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Randomized, Double-Blind, Phase 2 Study of the Effects of the Vaccine Vanutide Cridificar with QS-21 Adjuvant on Immunogenicity, Safety and Amyloid Imaging in Patients with Mild to Moderate Alzheimer's Disease.
    Ketter N; Liu E; Di J; Honig LS; Lu M; Novak G; Werth J; LePrince Leterme G; Shadman A; Brashear HR
    J Prev Alzheimers Dis; 2016; 3(4):192-201. PubMed ID: 29199321
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alzheimer's disease Advax(CpG)- adjuvanted MultiTEP-based dual and single vaccines induce high-titer antibodies against various forms of tau and Aβ pathological molecules.
    Davtyan H; Zagorski K; Rajapaksha H; Hovakimyan A; Davtyan A; Petrushina I; Kazarian K; Cribbs DH; Petrovsky N; Agadjanyan MG; Ghochikyan A
    Sci Rep; 2016 Jul; 6():28912. PubMed ID: 27363809
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.